{
    "organizations": [],
    "uuid": "008e0fe8e869e91edb3d0cc5972cbb77b7c8ee7f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cerenis-therapeutics-cash-position/brief-cerenis-therapeutics-cash-position-on-march-31-was-at-14-1-million-euros-idUSFWN1RW0V6",
    "ord_in_thread": 0,
    "title": "BRIEF-Cerenis Therapeutics Cash Position On March 31 Was At 14.1 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - CERENIS THERAPEUTICS HOLDING SA :\n* CASH POSITION AT MARCH 31 EUR 14.1 MILLION * DID NOT GENERATE ANY REVENUE DURING THE 1ST QUARTER OF 2018\n* ON APRIL 19, 1ST PATIENTS WERE DOSED IN PHASE I STUDY OF CER-209 IN NASH/NAFLD Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-20T00:57:00.000+03:00",
    "crawled": "2018-04-20T11:44:06.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "cerenis",
        "therapeutic",
        "holding",
        "sa",
        "cash",
        "position",
        "march",
        "eur",
        "million",
        "generate",
        "revenue",
        "1st",
        "quarter",
        "april",
        "1st",
        "patient",
        "dosed",
        "phase",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}